Genmab A/S (NASDAQ:GMAB) Cut to “Hold” at Zacks Research

Genmab A/S (NASDAQ:GMAB) was downgraded by equities researchers at Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

Several other analysts have also recently issued reports on GMAB. Truist Financial upped their target price on Genmab A/S from $45.00 to $46.00 and gave the company a “buy” rating in a report on Tuesday, July 8th. Wall Street Zen upgraded shares of Genmab A/S from a “hold” rating to a “buy” rating in a research report on Monday, July 28th. Finally, HC Wainwright boosted their target price on shares of Genmab A/S from $35.00 to $36.00 and gave the company a “buy” rating in a report on Friday, August 15th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Genmab A/S has an average rating of “Moderate Buy” and a consensus target price of $37.60.

Genmab A/S Price Performance

Shares of Genmab A/S stock opened at $24.06 on Tuesday. The stock has a market capitalization of $15.44 billion, a P/E ratio of 12.09, a PEG ratio of 6.91 and a beta of 0.95. The business has a 50 day simple moving average of $21.87 and a two-hundred day simple moving average of $21.00. Genmab A/S has a 12 month low of $17.24 and a 12 month high of $27.94.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.39 by $0.15. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%.The firm had revenue of $925.00 million for the quarter, compared to analyst estimates of $5.77 billion. Genmab A/S has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that Genmab A/S will post 1.45 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in GMAB. Headlands Technologies LLC grew its stake in shares of Genmab A/S by 1,525.0% in the first quarter. Headlands Technologies LLC now owns 1,560 shares of the company’s stock valued at $31,000 after buying an additional 1,464 shares in the last quarter. CWM LLC lifted its stake in Genmab A/S by 50.5% during the 2nd quarter. CWM LLC now owns 1,797 shares of the company’s stock worth $37,000 after acquiring an additional 603 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its stake in Genmab A/S by 124.3% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company’s stock worth $38,000 after acquiring an additional 1,070 shares in the last quarter. AlphaCore Capital LLC purchased a new position in Genmab A/S during the 2nd quarter valued at about $44,000. Finally, EverSource Wealth Advisors LLC grew its position in Genmab A/S by 124.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,114 shares of the company’s stock valued at $44,000 after acquiring an additional 1,174 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.